- Home
- THC vs RPRX Comparison
THC vs RPRX Comparison
Compare THC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THC
- RPRX
- Stock Information
- Founded
- THC 1967
- RPRX 1996
- Country
- THC United States
- RPRX United States
- Employees
- THC N/A
- RPRX N/A
- Industry
- THC Hospital/Nursing Management
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- THC Health Care
- RPRX Health Care
- Exchange
- THC Nasdaq
- RPRX Nasdaq
- Market Cap
- THC 17.7B
- RPRX 16.2B
- IPO Year
- THC N/A
- RPRX 2020
- Fundamental
- Price
- THC $200.96
- RPRX $39.68
- Analyst Decision
- THC Buy
- RPRX Strong Buy
- Analyst Count
- THC 19
- RPRX 3
- Target Price
- THC $217.89
- RPRX $46.00
- AVG Volume (30 Days)
- THC 1.1M
- RPRX 3.5M
- Earning Date
- THC 10-28-2025
- RPRX 11-05-2025
- Dividend Yield
- THC N/A
- RPRX 2.26%
- EPS Growth
- THC N/A
- RPRX N/A
- EPS
- THC 14.57
- RPRX 1.75
- Revenue
- THC $20,846,000,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- THC $3.67
- RPRX $36.16
- Revenue Next Year
- THC $4.52
- RPRX $2.04
- P/E Ratio
- THC $13.61
- RPRX $22.24
- Revenue Growth
- THC N/A
- RPRX 3.70
- 52 Week Low
- THC $109.82
- RPRX $24.05
- 52 Week High
- THC $217.43
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- THC 49.16
- RPRX 62.67
- Support Level
- THC $189.58
- RPRX $38.39
- Resistance Level
- THC $202.26
- RPRX $41.24
- Average True Range (ATR)
- THC 8.11
- RPRX 1.20
- MACD
- THC -1.43
- RPRX 0.18
- Stochastic Oscillator
- THC 41.18
- RPRX 71.62
About THC Tenet Healthcare Corporation
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.